HUTCHMED (China) Eulerpool News

HUTCHMED (China) Aktie News

HUTCHMED (China) wird von vielen Journalisten und Investoren weltweit beobachtet. Die aktuellsten HUTCHMED (China) News stellen wir hier zusammen.

• 3. Juli ·

  Yahoo
  HUTCHMED to Announce 2025 Half-Year Financial Results
• 30. Juni ·

  Yahoo
  HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
• 17. Juni ·

  SeekingAlpha
  Organon: Persistent Headwinds Make This A Hold
• 15. Juni ·

  Yahoo
  Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£231m last week
• 24. April ·

  Yahoo
  HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
• 22. April ·

  Yahoo
  HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
• 20. März ·

  Yahoo
  HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
• 19. März ·

  SeekingAlpha
  HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
• 19. März ·

  SeekingAlpha
  HUTCHMED (China) Limited 2024 Q4 - Results - Earnings Call Presentation
• 19. März ·

  Yahoo
  HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China